Jean-Yves Blay Named Among Oncology’s Moast Influential Leaders in 2025
Table of Contents
A leading voice in rare cancer research and equitable access to care, Professor Jean-Yves blay has been recognized as one of the 100 Most Influential People in Oncology for 2025, highlighting his decades of dedication to improving outcomes for patients with sarcomas, GISTs, and othre challenging cancers.
Professor Blay’s influence extends across multiple facets of the European cancer landscape. He currently serves as President of UNICANCER, the French Federation of Comprehensive Cancer Centres, and as General Director of the Centre Léon Bérard in Lyon – a major comprehensive cancer center.He also holds the position of Professor of Medical Oncology at Université Claude Bernard Lyon 1.
Pioneering Rare Cancer Networks Across Europe
A central tenet of Professor Blay’s work has been the establishment and strengthening of collaborative networks focused on rare adult solid cancers. He currently directs EURACAN, the European Reference Network, wich connects over 100 expert centers spanning 26 countries. This network is designed to enhance patient care, accelerate research, and facilitate cross-border access to specialized treatment.
His commitment to collaboration is further demonstrated by his previous leadership roles, including President of the European Organisation for Research and Treatment of Cancer (EORTC) from 2009 to 2012 and as Scientific President of the ESMO 2019 Congress.
Driving Innovation in Sarcoma Research and Genomic Medicine
Professor Blay has been described as “instrumental” in structuring both care and research initiatives for rare cancers. He coordinates NETSARC+, a French National Cancer institute-certified sarcoma network, and chairs the French Sarcoma Group, actively contributing to the world Sarcoma Network.
Moreover, he serves as Scientific Director of AURAGEN, a national whole-genome sequencing platform integral to France’s ambitious Genomic Medicine 2025 plan..
Championing Equity and Access in Cancer Care
Beyond research and network building, Professor Blay is a vocal advocate for equity in cancer care. He prioritizes the growth of sustainable systems that ensure all patients, particularly those with rare cancers, receive accurate diagnoses, access to cutting-edge innovation, and consistently high-quality care, not just within Europe, but globally.
His contributions have been widely recognized through numerous accolades, including ESMO’s Hamilton Fairley Award, prizes from the French National Academy of Medicine, and the prestigious Duquesne and San Salvatore prizes.
The recognition of Professor Blay as one of the 100 Most Influential People in Oncology underscores the importance of collaborative leadership and sustained dedication in the ongoing fight against cancer. The list, according to a statement released by the organization, aims to “recognize the changemakers in cancer care who have helped shape current practice and continue to drive innovation.” While acknowledging the limitations of any such list, the organization pledged to continue amplifying the voices of all dedicated professionals in the field through its ongoing publications.
The full list of The 100 Influential People in Oncology in 2